Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Home Topics

Litigation

Columns & Departments

Drug & Device News

ALM Staff & Law Journal Newsletters

Review of the latest news.

Columns & Departments

Med Mal News

ALM Staff & Law Journal Newsletters

A look at several recent news items.

Features

Foreseeable Harm to Third Parties Keeps Claim Against Drug Makers Alive

Janice G. Inman

Alabama's Supreme Court in January rendered a potentially far-reaching decision in a case pitting a consumer against drug manufacturers. While its holding applies only to cases brought in Alabama, the court's decision may lead to that state's becoming the preferred forum for certain types of drug litigation:

Features

Informed Consent and Res Ipsa Loquitur

Roseann Brenner & Elizabeth A. Syer

Two concepts that are mainstays of the medical malpractice arena are: 1) lack of informed consent; and 2) <I>res ipsa loquitu</I>r. Some plaintiffs may attempt to pursue these two theories in the same case. Is either of them ripe for dismissal?

Features

LegalVIEW Data Shows Litigation Up, Legal Spend Down

Sue Reisinger

The two hottest litigation areas these days are wage-and-hour and regulatory/compliance cases. But that isn't translating into more legal spending by corporate law departments.

Features

When Worlds Collide

Karen Grande, John Whitlock, Steven B. Smith & Theodore Orson

The first part of this article discussed the collision of the bankruptcy and public finance worlds, and the damage caused to bondholders and their respective professionals. The discussion concludes herein with a look at two additional rulings.

Features

Online Extra: Juror's Online Research Forces New Trial

Scott Graham

Jurors who improperly search the Internet for information about the trial they're hearing are a growing problem for lawyers and judges.

Columns & Departments

Bit Parts

Stan Soocher

Fifth Circuit Supports Perpetual License as Remedy for Video-Game Dispute<br>Musical Composition Doesn't Infringe Screenplay<br>Redigi Resales Case Factors Into Digital-Download Royalty Litigation

Features

Tax Planning for Nonresident Alien Artists

Andrew B. Blackman

The independent contractor nonresident alien (NRA) who has a high level of U.S. tax-related operating expenses may wish to consider the feasibility of obtaining a Central Withholding Agreement (CWA) or otherwise be saddled with 30% tax withholding on his or her gross fees.

Features

Expected Impact of Supreme Court First-Sale Ruling

Lisa Shuchman

The U.S. Supreme Court's recent ruling in <i>Kirtsaeng v. John Wiley &amp; Sons</i>, that a legally obtained copyrighted work can be imported into the United States and resold without permission from the copyright owner, even if it was manufactured and sold overseas, has broad legal ramifications going forward, intellectual property attorneys say.

Need Help?

  1. Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
  2. Need other assistance? email Customer Service or call 1-877-256-2472.

MOST POPULAR STORIES

  • Surveys in Patent Infringement Litigation: The Next Frontier
    Most experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.
    Read More ›
  • In the Spotlight
    On May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug &amp; Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.
    Read More ›